
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

